Orion Marine Group (ORN) reported $226.68 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 34.5%. EPS of $0.16 for the same period compares to $0.02 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $236.43 million, representing a surprise of -4.12%. The company delivered an EPS surprise of +100.00%, with the consensus EPS estimate being $0.08. While investors closely watch year-over-year changes in headline numbers -- revenue and ...

Orion Marine Group (ORN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this heavy civil marine contractor would post earnings of $0.03 per share when it actually produced a loss of $0.16, delivering a surprise of -633.33%.Over the last four ...

EXHIBIT 99.1 ORION GROUP HOLDINGS REPORTS THIRD QUARTER 2024 RESULTS HOUSTON – October 30, 2024 – Orion Group Holdings, Inc. (NYSE: ORN) (the "Company"), a leading specialty construction company, today reported its financial results for the third quarter ended September 30, 2024. Highlights for the quarter ended September 30, 2024: ● Contract revenues of $226.7 million ● GAAP net income of $4.3 million or $0.12 per diluted share ● Adjusted net income of $5.6 million or $0.16 per diluted share ● Adjusted EBI ...

HOUSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the "Company"), a leading specialty construction company, today reported its financial results for the third quarter ended September 30, 2024. Highlights for the quarter ended September 30, 2024: Contract revenues of $226.7 million GAAP net income of $4.3 million or $0.12 per diluted share Adjusted net income of $5.6 million or $0.16 per diluted share Adjusted EBITDA of $15.2 million Cash flow from operations of $35.2 million ...

MANITOWOC, Wis., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting and controls, electrical vehicle (EV) charging station solutions, and maintenance services, hosts conference call and webcast to review its fiscal 2025 second quarter (Q2'25) results on Wednesday, November 6, 2024 at 10:00 a.m. ET. Orion will release results prior to the market's opening that day. | --- | --- | |-------------------------|----------------- ...

LOS ANGELES and MANITOWOC, Wis., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging stations and maintenance services solutions, today announced unaudited preliminary revenue results for its fiscal 2025 second quarter (Q2'25) ended September 30, 2024, in anticipation of its participation today at the LD Micro Main Event XVII investor conference in Los Angeles. CEO Mike Jenkins and CFO Per B ...

Here are more of the features available to you. And there's nothing to lose with our FREE 2-week trial. Just click this link . Join iREIT® on Alpha today... for more in-depth research on REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. You'll get more articles throughout the week, and access to our Ratings Tracker with buy/sell recommendations on all the stocks we cover. Plus unlimited access to our multi-year Archive of articles. I'm sure that you've seen me writing about "sleep w ...

Collaboration and Regulatory Submission - Bayer, Orion's collaboration partner, submitted an application to the European Medicines Agency (EMA) for the use of darolutamide in combination with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) [1] - The submission is based on positive results from the Phase III ARANOTE trial, which showed a 46% reduction in the risk of radiological progression or death compared to placebo plus ADT in mHSPC patients [1] Market Approvals and Global Reach - Darolutamide, marketed as Nubeqa™, is already approved for mHSPC in combination with ADT and docetaxel in over 80 markets worldwide [2] - The compound is also approved in more than 85 countries for non-metastatic castration-resistant prostate cancer (nmCRPC) in combination with ADT [2] Company Overview - Orion is a globally operating Finnish pharmaceutical company with a focus on oncology and pain therapy areas [3] - The company develops, manufactures, and markets human and veterinary pharmaceuticals, with a portfolio including proprietary and generic medicines and consumer health products [3] - Orion's net sales in 2023 amounted to EUR 1,190 million, and the company employed approximately 3,600 people at the end of the year [3]

I analyze oil and gas companies, related companies, and Orion Office REIT in my service, Oil & Gas Value Research, where I look for undervalued names in the oil and gas space. I break down everything you need to know about these companies -- the balance sheet, competitive position and development prospects. This article is an example of what I do. But for Oil & Gas Value Research members, they get it first and they get analysis on some companies that is not published on the free site. Interested? Sign up he ...

LOS ANGELES and MANITOWOC, Wis., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging station, and maintenance service solutions, announced it will be presenting at the LD Micro Main Event XVII at the Luxe Sunset Boulevard Hotel, on Tuesday, October 29th at 8:30 a.m. PT / 11:30 a.m. ET. CEO Mike Jenkins and CFO Per Brodin will also be available throughout the day on Tuesday and Wednesday morn ...